Stockpolly
Search
FULC · NASDAQ · Biotechnology

Fulcrum Therapeutics (FULC)

Maintains small-molecule gene-regulation capabilities while reviewing strategic alternatives.

$3.89
Pre-market+0.04 (+1.17%)
At close$3.85(−0.65%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue1108000000000
Cost of revenue18101715013014000
Gross profit−170063−150−130−14000
1028291010197208232220
Research & development181919171511131314151412
109101088778787
Selling & marketing1−10000000000
General & administrative910101080777787
Other expenses−1800−17−130−130−14000
Operating income−27−28−3052−25−19−20−20−22−23−22−20
33333333223−6
Other non-operating income0−3−3−3−2−3−3−3−2−2−30
Income before tax−24−25−2755−22−17−18−17−20−20−19−26
Net income from continuing operations−24−25−2755−22−17−18−17−20−20−19−26
Net income−24−25−2755−22−17−18−17−20−20−19−26
EPS, basic−$0.39−$0.40−$0.43$0.89−$0.35−$0.31−$0.28−$0.28−$0.31−$0.31−$0.25−$0.34
EPS, diluted−$0.39−$0.40−$0.43$0.87−$0.35−$0.31−$0.28−$0.28−$0.31−$0.31−$0.25−$0.34
Weighted average shares, basic626262626254626363637676
Weighted average shares, diluted626262646254626363637676
EBITDA−27−24−2656−23−16−17−17−19−20−19−20
Depreciation & amortization110000000000
EBIT−27−25−2755−23−17−18−17−20−20−19−20